1. Home
  2. Companies
  3. IMM
  4. Material Events

Immutep (ASX:IMM) — Material Events

ASX:IMM · 22 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 18 articles Notable 3 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
18
Immutep Secures FDA Orphan Drug Status for Eftilagimod Alfa in Soft Tissue SarcomaMedium
Immutep awarded FDA Orphan Drug Designation for eftilagimod alfa in Soft Tissue Sarcoma
15 Apr 2026 ·Regulatory Announcement ·85
Immutep Secures $20M Upfront in Global Deal for Cancer Drug EftiMedium
Immutep licenses Eftilagimod Alfa to Dr. Reddy’s for key emerging markets with $20M upfront and $349.5M milestones
8 Dec 2025 ·Strategic Collaboration / Licensing Agreement ·85
Immutep Halts Key Phase III NSCLC Trial After Futility CallHigh
Immutep halts TACTI-004 Phase III NSCLC trial after futility analysis
13 Mar 2026 ·Clinical Trial Update ·Unexpected ·85
FDA Signals Support for Immutep’s Eftilagimod Alfa in Hard-to-Treat Head and Neck CancerMedium
Immutep gets FDA backing for eftilagimod alfa in head and neck cancer with low PD-L1 expression
5 Aug 2025 ·Regulatory Update ·85
Immutep’s LAG-3 Immunotherapies Gain Traction with Strong Trial Data and Robust Cash ReservesMedium
Immutep advances multiple clinical trials with strong interim data and solid cash reserves
30 July 2025 ·Quarterly Activities Report & Appendix 4C ·85
Immutep’s Efti Combo Sparks Hope for Tough-to-Treat Lung Cancer PatientsMedium
Immutep’s Efti Combo Shows Strong Response Rates in First Line NSCLC at ESMO 2025
20 Oct 2025 ·Clinical Trial Data Announcement ·85
Immutep’s Efti Combo Sparks Immune Surge in Hard-to-Treat SarcomasMedium
Immutep's EFTISARC-NEO Phase II trial shows strong efficacy and immune activation in soft tissue sarcoma
13 Nov 2025 ·Clinical Trial Results ·85
Immutep’s Efti Combo Surpasses Tumor Response Expectations in Soft Tissue SarcomaMedium
Immutep’s Phase II Trial of Efti Combo in Soft Tissue Sarcoma Exceeds Primary Endpoint with 51.5% Tumor Response
20 Oct 2025 ·Clinical Trial Results ·85
Immutep Advances Global Phase III Lung Cancer Trial with 38% EnrolmentMedium
Immutep's Phase III TACTI-004 Trial Shows Robust Enrolment and Global Progress
16 Dec 2025 ·Clinical Trial Progress Update ·85
Immutep Advances Phase III Lung Cancer Trial Amid Rising FY25 LossesHigh
Immutep reports FY2025 loss of A$61.4M, advances Phase III lung cancer trial, maintains strong cash runway
29 Aug 2025 ·Preliminary Final Report ·85
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer TrialMedium
Immutep advances multiple clinical trials with strong enrollment and FDA support, maintains robust cash position
29 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Immutep Secures FDA Nod on Efti Dose, Accelerates Lung Cancer TrialMedium
Immutep Secures FDA Agreement on Optimal Dose for Efti, Advances Phase III NSCLC Trial
13 Oct 2025 ·Regulatory Update ·85
Immutep’s IMP761 Shows Promising Immunosuppressive Effects in Phase I TrialMedium
Immutep Reports Positive Phase I Results for IMP761 LAG-3 Agonist in Autoimmune Diseases
22 Dec 2025 ·Clinical Trial Update ·85
Immutep Defines Optimal Dose for Eftilagimod Alfa in Breast Cancer TrialMedium
Immutep presents positive Phase II breast cancer data, defines optimal dose for eftilagimod alfa
2 Dec 2025 ·Clinical Trial Data Presentation ·80
Immutep Hits 50% Enrolment in Pivotal Lung Cancer TrialMedium
Immutep Reaches Halfway Enrolment Milestone in Phase III Lung Cancer Trial
6 Feb 2026 ·Clinical Trial Update ·80
Immutep Surpasses Enrollment Milestone in Pivotal Lung Cancer TrialMedium
Immutep's Phase III NSCLC Trial Surpasses Enrollment Milestone, Futility Analysis on Track for Early 2026
9 Oct 2025 ·Clinical Trial Update ·80
Immutep Advances IMP761 with Strong Phase I Safety and Immunosuppressive SignalsMedium
Immutep reports positive Phase I results for LAG-3 agonist IMP761 in autoimmune diseases
19 Mar 2026 ·Clinical Trial Update ·80
Immutep Reports Mature 30.9-Month Survival in 1L NSCLC but TACTI-004 Trial HaltedMedium
Immutep reports positive mature survival data in 1L NSCLC from INSIGHT-003; TACTI-004 trial discontinued with ongoing root cause analysis
13 July 2026 ·Clinical Trial Update ·Unexpected ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.